As you have found, STAMPEDE's new updated website has launched. This website is a tool for stakeholders of the STAMPEDE research, assisting in such aspects as the provision of information, running of the trial and the dissemination of results. Browse the tabs and understand what is just a click away. Don't forget to check regularly for updates and keep us in your favourites! ...
The latest results from the Stampede trial in prostate cancer look to confirm a seismic shift in the treatment landscape in favour of Johnson & Johnson’s ageing Zytiga, but the impact for the whole industry – following a study run by academics – could be even more significant.
Check out the latest press, resulting from STAMPEDEs presentations across the European Society for Medical Oncology (ESMO) conference, through the EPVantage link below!
Systematic review confirms that adding abiraterone to hormone therapy improves survival for men whose prostate cancer has spread
Results of a systematic review including two large trials have confirmed that adding a drug called abiraterone to standard long-term hormone therapy helps men with prostate cancer that has spread to live longer. These results, from the STOPCaP study, were published this week in the European Journal of Cancer. Abiraterone is a type of hormone therapy currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. Both trials tested using it earlier, in men starting long-term standard hormone therapy for the first time. Overall, the results showed that adding abiraterone to standard hormone therapy reduced the risk of death by 38%. This means that after three years, 69 out of 100 men who received abiraterone were alive compared to 55 out of 100 men who just had standard hormone therapy. Abiraterone also reduces the risk of prostate cancer getting worse by 55%. This means that after three years, 58 out of 100 men who received abirater ...
PSA Doubling Time Calculator
For the purposes of the STAMPEDE trial, an online PSA doubling time value calculator has been linked to allow sites to calculate this PSA velocity easier. We hope with the linking of this calculator it will be easier for you to track a patient’s PSA record. For more details see the tools and training section here. ...
Arm L Activation
The Stampede team are pleased to announce that the "transdermal oestradiol comparison" (Arm L) was activated today (20/06/2017) at 9am. We have 40 sites ready to randomise and we will continue to re-open sites as quickly as possible. Congratulations to all sites that were ready on Day 1! If you are yet to receive a green light activation you cannot randomise. To complete the activation process look here. ...
MRC Clinical Trials Unit at UCL
90 High Holborn